Literature DB >> 12396626

New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication.

Ruben Hernandez-Alcoceba1, Michael Pihalja, Dalong Qian, Michael F Clarke.   

Abstract

Oncolytic adenoviruses with restricted replication can be produced if the expression of crucial transcription units of the virus is controlled by tissue- or tumor-specific promoters. Here we describe a method for the rapid incorporation of exogenous promoters into the E1A and E4 regions of the human adenovirus type 5 genome. Using this system, we have generated AdEHT2 and AdEHE2F, two conditionally replicative adenoviruses for the treatment of breast cancer. The expression of the E1A gene in both viruses is controlled by a minimal dual-specificity promoter that responds to estrogens and hypoxia. The tight regulation of E1A expression correlated with the ability of these viruses to replicate and kill human cancer cells that express estrogen receptors, or are maintained under hypoxic conditions. The telomerase reverse transcriptase (TERT) promoter and the E2F-1 promoter are preferentially activated in cancer cells. They were introduced into the E4 region of AdEHT2 and AdEHE2F, respectively. The telomerase core promoter failed to block the replication of the virus in telomerase-negative cells. In contrast, AdEHE2F was attenuated in nontransformed quiescent cells growing under normoxic conditions, suggesting that an intact pRB pathway with low levels of E2F transcription factors acts as a negative modulator for the virus. These data indicate that the simultaneous regulation of E1A and E4 viral transcription units by the appropriate combination of promoters can increase the tumor selectivity of oncolytic adenoviruses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12396626     DOI: 10.1089/104303402760293574

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  24 in total

1.  Potent antitumoral efficacy of a novel replicative adenovirus CNHK300 targeting telomerase-positive cancer cells.

Authors:  C-Q Su; J Sham; H-B Xue; X-H Wang; D Chua; Z-F Cui; L-H Peng; L-F Li; L-H Jiang; M-C Wu; Q-J Qian
Journal:  J Cancer Res Clin Oncol       Date:  2004-07-09       Impact factor: 4.553

2.  HSV Recombinant Vectors for Gene Therapy.

Authors:  Roberto Manservigi; Rafaela Argnani; Peggy Marconi
Journal:  Open Virol J       Date:  2010-06-18

3.  Antitumor activity of an hTERT promoter-regulated tumor-selective oncolytic adenovirus in human hepatocellular carcinoma.

Authors:  Chang-Qing Su; Xing-Hua Wang; Jie Chen; Yong-Jing Liu; Wei-Guo Wang; Lin-Fang Li; Meng-Chao Wu; Qi-Jun Qian
Journal:  World J Gastroenterol       Date:  2006-12-21       Impact factor: 5.742

4.  Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice.

Authors:  Devanand Sarkar; Zao-Zhong Su; Nicolaq Vozhilla; Eun Sook Park; Pankaj Gupta; Paul B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-19       Impact factor: 11.205

5.  Tumor-specific gene expression using the survivin promoter is further increased by hypoxia.

Authors:  L Yang; Z Cao; F Li; D E Post; E G Van Meir; H Zhong; W C Wood
Journal:  Gene Ther       Date:  2004-08       Impact factor: 5.250

Review 6.  Adenoviral vectors for prodrug activation-based gene therapy for cancer.

Authors:  Joshua C Doloff; David J Waxman
Journal:  Anticancer Agents Med Chem       Date:  2014-01       Impact factor: 2.505

Review 7.  Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer.

Authors:  Dirk M Nettelbeck
Journal:  J Mol Med (Berl)       Date:  2007-12-19       Impact factor: 4.599

8.  Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters.

Authors:  Sergia Bortolanza; Maria Bunuales; Itziar Otano; Gloria Gonzalez-Aseguinolaza; Carlos Ortiz-de-Solorzano; Daniel Perez; Jesus Prieto; Ruben Hernandez-Alcoceba
Journal:  Mol Ther       Date:  2009-02-17       Impact factor: 11.454

9.  E2F promoter-regulated oncolytic adenovirus with p16 gene induces cell apoptosis and exerts antitumor effect on gastric cancer.

Authors:  Juming Ma; J Ma; Xiaoping He; X He; Weiguo Wang; W Wang; Yao Huang; Y Huang; Lin Chen; L Chen; Wenming Cong; W Cong; Jianzhong Gu; J Gu; Huizhen Hu; H Hu; Jianguo Shi; J Shi; Linfang Li; L Li; Changqing Su; C Su
Journal:  Dig Dis Sci       Date:  2008-11-26       Impact factor: 3.199

10.  Potent anti-tumor effects of a dual specific oncolytic adenovirus expressing apoptin in vitro and in vivo.

Authors:  Xiao Li; Yan Liu; Zhongmei Wen; Chang Li; Huijun Lu; Mingyao Tian; Kuoshi Jin; Lili Sun; Pegn Gao; Encheng Yang; Xiaohong Xu; Shifu Kan; Zhuoyue Wang; Yuhang Wang; Ningyi Jin
Journal:  Mol Cancer       Date:  2010-01-20       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.